Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicago Inc MDCGF

GREY:MDCGF - Post Discussion

Medicago Inc > Note to blueocean12:Uchuck's "cold shower" on MDG
View:
Post by uchuck on Jul 05, 2013 3:33pm

Note to blueocean12:Uchuck's "cold shower" on MDG

You did not read my Note # 1:said I'd be back on July 23rd after I've taken a "cold shower," have yet to own MDG. "Going long" is for poets and dreamers, but if it works for you, I'm happy.
Comment by Blueocean102 on Jul 05, 2013 4:23pm
Well...I've been told I'll never succeed as a poet...So I'm left with the dreamer alternative...  :-)            Have a nice week-end.
Comment by kungfu010 on Jul 06, 2013 2:26am
Adimmune Corp said its H7N9 influienza vaccine developed from a WHO-approved virus strain has recently passed the 3rd phase of clinical trials, signifying the vaccine will hit the shelves anytime soon. Adimmune is a Taiwan-based top-tier vaccine provider & Asia's only EU-GMP-certified pharmaceutical company.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities